UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 131

of 'Cutaneous side effects of conventional chemotherapy agents'

131
TI
Dapsone in prevention of recurrent neutrophilic eccrine hidradenitis.
AU
Shear NH, Knowles SR, Shapiro L, Poldre P
SO
J Am Acad Dermatol. 1996;35(5 Pt 2):819.
 
Neutrophilic eccrine hidradenitis has been described in patients with acute myelogenous leukemia and other malignant diseases, usually during chemotherapy. We describe a 46-year-old man with Hodgkin's disease in whom neutrophilic eccrine hidradenitis developed after each of the first two treatments with lomustine. Dapsone, 100 mg daily, was initiated 48 hours before the patient's third treatment with lomustine and was continued for 14 days. This regimen was successful in suppressing the reaction during the first course and three subsequent courses of lomustine.
AD
Division of Dermatology, Sunnybrook Health Science Centre, University of Toronto, Ontario, Canada.
PMID